“To DRE or not to DRE, that is the question”

With apologies to the Bard of Avon and his character Hamlet, the above-misquoted Prince of Denmark, we bring to your attention the most recent article by our good friend Howard Wolinsky on issues related to prostate cancer. … READ MORE …

Yes, you are at risk … but risk of exactly what?

An article just published in Urologic Oncology has reported — perhaps not surprisingly — that men who have a single, initial negative biopsy as a consequence of suspicion of prostate cancer are at significant risk for actual diagnosis of prostate cancer over the next 20 years. … READ MORE …

Modern prostate cancer imaging: application of the right scan at the right time

A new “opinion” article in the Journal of Clinical Oncology this week has addressed the complex issue of how best to think about (a) how we are regulating use of and (b) how we are applying new forms of imaging technique in the management of prostate cancer … READ MORE …

Risk for suicide among prostate cancer patients

An article just published in the journal Cancer states that — at least here in the USA — there was no significant increase in risk for suicide within the first year after diagnosis among men diagnosed with prostate cancer between 2000 and 2014 … READ MORE …

Maybe coming soon to a medical center near you?

Our regular readers will remember that we have commented on and off on the development of different types of system that (maybe) can be used to test for risk of cancer based on smell … an ability that has been clearly demonstrated among certain trained dogs and one of two electronic systems. … READ MORE …

Computer modeling, genomics, and prostate cancer prognosis

A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that

Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …

The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …